Invion Limited (ASX:IVX) Completes $2M Share Placement to Advance Clinical Programs
Invion Limited (ASX:IVX) successfully raises $2M through a share placement to fund its Phase I/II cancer clinical trials.
Category: Healthcare
Biotron Limited (ASX:BIT) Withdraws Share Purchase Plan and Launches Rights Issue
Biotron Limited (ASX:BIT) withdraws its Share Purchase Plan and announces a $750,000 Rights Issue with Mahe Capital to secure its financial position.
Imricor Medical Systems (ASX:IMR) Submits Second FDA PMA Module
Imricor Medical Systems (ASX:IMR) submits its second FDA PMA module, advancing regulatory progress and preparing for upcoming product launches.
Firebrick Pharma (ASX:FRE) Secures $1.1M Strategic Investment from Philippines Partner
Firebrick Pharma (ASX:FRE) secures a $1.1 million strategic investment from Pharma Nutria N.A., Inc., strengthening its partnership in the Philippines.
Dimerix Limited (ASX:DXB) Receives Initial Upfront Payment from FUSO
Dimerix Limited (ASX:DXB) receives an initial ¥300 million payment from FUSO, with further milestones and potential royalties outlined.
Pro Medicus Limited (ASX:PME) Secures A$40M, 7-Year Contract with LucidHealth
Pro Medicus Limited (ASX:PME) signs a A$40M, 7-year contract with LucidHealth to implement its cloud-based Visage 7 platform.
PainChek Limited (ASX:PCK) Releases Half Year Results
PainChek Limited (ASX:PCK) reports a 27% revenue increase in its half-year results, highlighting growth and expansion into the US market.
The Hydration Pharmaceuticals Company Limited (ASX:HPC) Reports FY2024 Financial Results
The Hydration Pharmaceuticals Company Limited (ASX:HPC) reports a 25.5% revenue decline in FY2024, asset divestiture, and a strategic focus on US growth.
Epsilon Healthcare (ASX:EPN) Reports 43% Revenue Growth and Significant Loss Reduction for 2023
Epsilon Healthcare (ASX:EPN) reports a 43% revenue increase and a 92% reduction in net loss for 2023, alongside entering Voluntary Administration.
ECS Botanics Holdings Ltd (ASX:ECS) Reports Half-Year Financial Results
ECS Botanics Holdings Ltd (ASX:ECS) reports a $1.98m net loss and strategic expansions in export markets and product offerings.